Holen Sie sich die Stockscreener-App
42.80
0.58%
-0.25
Handel nachbörslich:
42.81
0.01
+0.02%
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
How institutional ownership impacts Mineralys Therapeutics Inc. stockQuarterly Performance Summary & Technical Buy Zone Confirmation - newser.com
Real time pattern detection on Mineralys Therapeutics Inc. stockWeekly Trade Review & AI Enhanced Market Trend Forecasts - newser.com
Mineralys Therapeutics Inc. stock chart pattern explainedTrade Volume Summary & Fast Entry and Exit Trade Plans - newser.com
Will Mineralys Therapeutics Inc. stock maintain growth storyJuly 2025 Rallies & Daily Price Action Insights - newser.com
Applying big data sentiment scoring on Mineralys Therapeutics Inc.Trade Entry Report & Step-by-Step Swing Trade Plans - newser.com
Published on: 2025-10-13 10:33:38 - newser.com
Can machine learning forecast Mineralys Therapeutics Inc. recoveryEarnings Trend Report & Growth Focused Stock Pick Reports - newser.com
How to use Fibonacci retracement on Mineralys Therapeutics Inc.Earnings Summary Report & Consistent Income Trade Recommendations - newser.com
Real time scanner hits for Mineralys Therapeutics Inc. explainedIndex Update & Free Low Drawdown Momentum Trade Ideas - newser.com
Published on: 2025-10-13 08:29:11 - newser.com
What MACD signals say about Mineralys Therapeutics Inc.2025 Short Interest & Fast Gaining Stock Reports - newser.com
A Look at Mineralys Therapeutics's Valuation as Phase 2 EXPLORE-OSA Trial Reaches Enrollment Milestone - simplywall.st
Has Mineralys Therapeutics Inc. formed a bullish divergenceQuarterly Market Summary & Reliable Breakout Forecasts - newser.com
Understanding Mineralys Therapeutics Inc.’s price movementShare Buyback & Real-Time Buy Signal Notifications - newser.com
Mineralys Therapeutics (NASDAQ:MLYS) Sets New 52-Week HighShould You Buy? - MarketBeat
Mineralys Therapeutics (MLYS) Is Up 10.8% After Completing Phase 2 OSA Trial Enrollment – What's Changed - simplywall.st
Mineralys Therapeutics stock hits all-time high at 41.11 USD By Investing.com - Investing.com Nigeria
Mineralys Therapeutics stock hits all-time high at 41.11 USD - Investing.com
Mineralys Therapeutics (NASDAQ:MLYS) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Published on: 2025-10-10 04:36:23 - newser.com
Is Mineralys Therapeutics Inc. stock reversal real or fakeJuly 2025 Catalysts & Weekly High Momentum Picks - newser.com
Forecasting Mineralys Therapeutics Inc. price range with options dataTrade Signal Summary & Consistent Profit Trade Alerts - newser.com
EXPLORE-OSA Drug Candidate Trial Fully Enrolled - Sleep Review
Real time breakdown of Mineralys Therapeutics Inc. stock performanceJuly 2025 Levels & Reliable Momentum Entry Alerts - newser.com
Can Mineralys Therapeutics Inc. recover in the next quarterEarnings Risk Report & Fast Momentum Entry Tips - newser.com
Published on: 2025-10-09 03:22:25 - newser.com
Tick level data insight on Mineralys Therapeutics Inc. volatility2025 Biggest Moves & Real-Time Sentiment Analysis - newser.com
Will Mineralys Therapeutics Inc. see short term momentumJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Mineralys Therapeutics Announces Q1 2025 Financial Results and Achievements - MSN
What drives Mineralys Therapeutics Inc stock priceEarnings Season Recap & Low Risk Trading Ideas - earlytimes.in
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring a 15% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Can swing trading help recover from Mineralys Therapeutics Inc. lossesJuly 2025 Retail & Technical Confirmation Trade Alerts - newser.com
Applying Wyckoff theory to Mineralys Therapeutics Inc. stockWeekly Trend Recap & Expert Curated Trade Setup Alerts - newser.com
What’s next for Mineralys Therapeutics Inc. stock priceJuly 2025 Market Mood & Safe Entry Point Alerts - newser.com
Mineralys Therapeutics Inc.’s volatility index tracking explained2025 Momentum Check & Weekly Return Optimization Alerts - newser.com
Mineralys Completes Enrollment in Phase 2 Sleep Apnea and Hypertension Trial - MyChesCo
Is Mineralys Therapeutics Inc. stock poised for growthTrade Entry Summary & Scalable Portfolio Growth Ideas - newser.com
Tools to assess Mineralys Therapeutics Inc.’s risk profileJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com
Statistical indicators supporting Mineralys Therapeutics Inc.’s strengthJuly 2025 Action & Community Consensus Stock Picks - newser.com
What does recent volatility data suggest for Mineralys Therapeutics Inc.Market Sentiment Review & Safe Swing Trade Setup Alerts - newser.com
Top chart patterns to watch in Mineralys Therapeutics Inc.2025 Market WrapUp & Expert Approved Trade Ideas - newser.com
Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 5.2%Here's Why - MarketBeat
Could Mineralys Therapeutics (MLYS) Trial Progress Hint at a Broader Hypertension Strategy? - simplywall.st
Mineralys Therapeutics Announces Public Offering of Shares - MSN
uniQure, Dianthus Therapeutics, and Mineralys Therapeutics Lead September 2025 Biotech Funding Rounds - geneonline.com
The biggest biotech funding rounds in September 2025 - Labiotech.eu
Why Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension Trial - Yahoo Finance
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):